Wang et al., have shown that hnRNPC is overexpressed in prostate cancer, correlating with poor clinical outcomes and inhibiting tumor proliferation and metastasis when silenced, suggesting its potential as a prognostic and therapeutic target [34]. The gene discussed is HNRNPC; the disease is neoplasm.